Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Condition Directory

Lymphoma clinical trials

Directory of U.S. ClinicalTrials.gov public records for Lymphoma. Browse Lymphoma recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced May 21, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
856
Shown on this page
12
Local recruiting
59
Local phase groups
6
The trial list below is retrieved from the live ClinicalTrials.gov search API for Lymphoma. Results on this page are currently sorted by Recently updated.

Filter and sort this condition

These controls apply only within Lymphoma. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 1–12 of 856 matching trials for Lymphoma.
Indexed local directory records.

Phase distribution

Phase 2 409
Phase 1 308
Not applicable 71
Phase 3 63
Early Phase 1 9
Phase 4 3

Top locations

New York, New York 187 Houston, Texas 145 Chicago, Illinois 118 Boston, Massachusetts 118 Baltimore, Maryland 101 Los Angeles, California 96

Top sponsors

Memorial Sloan Kettering Cancer Center 61 M.D. Anderson Cancer Center 54 National Cancer Institute (NCI) 42 Alliance for Clinical Trials in Oncology 34 Fred Hutchinson Cancer Center 25 SWOG Cancer Research Network 22

Top therapies

cyclophosphamide 140 filgrastim 101 rituximab 96 peripheral blood stem cell transplantation 78 etoposide 73 radiation therapy 61

Indexed official records

Open in full search
Recruiting No phase listed Observational

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

NCT05011045
View directory record Official record
Conditions
Central Nervous System Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma, Secondary Central Nervous System Lymphoma
Interventions
Magnetic Resonance Imaging, Neurocognitive Assessment, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 12:56 AM EDT
Recruiting Not applicable Interventional

xDRIVE for Florida-based Cancer Patients

NCT07167381
View directory record Official record
Conditions
Cancer, Leukaemia, Lymphoma, Neoplams, Recurrence, Refractory, Solid Cancers, Solid Tumor Malignancies
Interventions
xDRIVE Tumor Profiling
Diagnostic Test
Lead sponsor
First Ascent Biomedical Inc.
Industry
Eligibility
Not listed
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 20, 2026, 1:20 AM EDT
Recruiting Phase 1Phase 2 Interventional

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

NCT06137144
View directory record Official record
Conditions
AITL, ALCL, Hodgkin Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, PTCL-NOS, Peripheral T-cell Lymphoma (PTCL)
Interventions
AZD3470, Pembrolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
7
States / cities
Duarte, California • Miami, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 21, 2026, 1:11 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

NCT05237986
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
Los Angeles, California • Bethesda, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 19, 2026, 11:00 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

NCT02332668
View directory record Official record
Conditions
Classical Hodgkin Lymphoma, Lymphoma, Melanoma, Microsatellite-instability-high Solid Tumor, Solid Tumor
Interventions
Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
6 Months to 17 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 20, 2026, 10:23 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

NCT05683171
View directory record Official record
Conditions
Lymphoma
Interventions
Lenalidomide, Rituximab, Valemetostat
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 19, 2026, 8:32 AM EDT
Recruiting Phase 2 Interventional

Cord Blood Transplantation in Children and Young Adults With Blood Cancer

NCT07566377
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Graft-versus-host Disease, Hodgkin Lymphoma, Leukemia, Lymphoma, Myelodysplastic Syndromes, Non-hodgkin Lymphoma
Interventions
Busulfan, Clofarabine, Cord Blood Units, Cyclophosphamide, Cyclosporine, Fludarabine, Mycophenolate Mofetil, Tacrolimus, Thiotepa, Total Body Irradiation
Drug · Biological · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 26 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 21, 2026, 1:18 AM EDT
Recruiting Phase 2 Interventional

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

NCT03258567
View directory record Official record
Conditions
Disorders, Lymphoproliferative, Epstein-Barr Virus Infections, Lymphoma, Lymphoproliferative Disorder
Interventions
Nivolumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced May 19, 2026, 8:49 PM EDT
Recruiting Phase 1 Interventional

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT06624085
View directory record Official record
Conditions
Lymphoma
Interventions
Gemcitabine, Glofitamab, Obinutuzumab, Oxaliplatin, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
15
States / cities
La Jolla, California • Laguna Hills, California • Santa Monica, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 21, 2026, 1:22 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

NCT06084936
View directory record Official record
Conditions
Lymphoma
Interventions
Bendamustine, Glofitamab, Lenalidomide, Obinutuzumab, Rituximab, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
18
States / cities
Berkeley, California • Duarte, California • Santa Monica, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 20, 2026, 12:22 AM EDT
Recruiting Phase 1 Interventional

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

NCT06441331
View directory record Official record
Conditions
CNS Tumors, GIST, Lymphoma, NETs, Peripheral Primitive Neuroectodermal Tumor, Rhabdomyosarcoma, Solid Tumor, Somatostatin Receptor Positive
Interventions
Amino Acid Solution, Lutetium Lu 177-Edotreotide
Other · Drug
Lead sponsor
ITM Solucin GmbH
Industry
Eligibility
24 Months to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 12:56 AM EDT
Recruiting Phase 1 Interventional

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

NCT04739813
View directory record Official record
Conditions
Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Lymphoma, Non-Hodgkin Lymphoma
Interventions
Polatuzumab, Revlimid, ibrutinib, obinutuzumab, prednisone, venetoclax
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced May 21, 2026, 1:22 AM EDT

About this Lymphoma clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Lymphoma as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lymphoma.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Lymphoma.